Ceribell, Inc. (NASDAQ: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, has announced the appointment of Erica Rogers to its board of directors. Rogers, an accomplished healthcare executive with over three decades of experience leading high-growth, innovative medical device companies, brings proven strategic leadership and expertise in scaling high-growth healthcare companies to Ceribell.
Rogers most recently served as chief executive officer of Silk Road Medical, Inc., leading the business from its early stages through FDA approval and broad commercial expansion, which ultimately resulted in acquisition by Boston Scientific Corporation. During her tenure, the organization grew significantly from a 25-person startup to a 500-employee, publicly-traded company with revenue exceeding $175 million.
Ceribell is currently at a pivotal growth phase as it expands nationwide access to its point-of-care EEG system to help clinicians deliver timely care for critically ill patients. The company's impact has already improved care for hundreds of thousands of critically ill patients in more than 550 hospitals.
With the addition of Erica Rogers to its board of directors, Ceribell aims to leverage her experience in scaling healthcare companies and driving adoption of new technologies in clinical practice as it works to establish the Ceribell system as the standard of care.
This appointment comes as Ceribell continues to pioneer a new era of timely brain monitoring, positively transforming patient outcomes with its groundbreaking rapid EEG technology. Today the company's shares have moved -2.47% to a price of $12.25. For the full picture, make sure to review Ceribell's 8-K report.
